Chiara Gallio
Overview
Explore the profile of Chiara Gallio including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
20
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Matteucci L, Sullo F, Gallio C, Esposito L, Muratore M, Rapposelli I, et al.
Int J Mol Sci
. 2024 Oct;
25(20).
PMID: 39456850
The efficacy and cost-effectiveness of Multigene Panel Next-Generation Sequencing (NGS) in directing patients towards genomically matched therapies remain uncertain. This study investigated metastatic colorectal cancer (mCRC) patients who underwent NGS...
2.
Coussement M, Fazio R, Audisio A, El Khoury R, Abbassi F, Assaf I, et al.
Cancers (Basel)
. 2024 Jul;
16(14).
PMID: 39061244
Immune checkpoint inhibitors and immune-related biomarkers are increasingly investigated in rectal cancer (RC). We retrospectively analysed PD-L1 expression in diagnostic biopsy and resection samples from RC patients treated at our...
3.
Sclafani F, Conti C, Gallio C, Hendlisz A
Curr Opin Oncol
. 2024 Jun;
36(4):305-307.
PMID: 38842017
No abstract available.
4.
Sullo F, Passardi A, Gallio C, Molinari C, Marisi G, Pozzi E, et al.
J Clin Med
. 2024 May;
13(9).
PMID: 38731090
Rectal cancer presents a significant burden globally, often requiring multimodal therapy for locally advanced cases. Long-course chemoradiotherapy (LCRT) and short-course radiotherapy (SCRT) followed by surgery have been conventional neoadjuvant approaches....
5.
Passardi A, Azzali I, Bittoni A, Marisi G, Rebuzzi F, Molinari C, et al.
Ther Adv Med Oncol
. 2023 Dec;
15:17588359231212184.
PMID: 38107830
Background: Validated predictors of sensitivity or resistance to Bevacizumab (Bev) are not available, and Inflammatory Indexes (IIs) has been reported to be useful prognostic factors in various malignant solid tumours,...
6.
Urbini M, Marisi G, Azzali I, Bartolini G, Chiadini E, Capelli L, et al.
JCO Precis Oncol
. 2023 Sep;
7:e2200694.
PMID: 37656949
Purpose: Plasma circulating tumor DNA (ctDNA) is a valuable resource for tumor characterization and for monitoring of residual disease during treatment; however, it is not yet introduced in metastatic colorectal...
7.
Monti M, Prochowski Iamurri A, Bianchini D, Gallio C, Esposito L, Montanari D, et al.
Nutrients
. 2023 Aug;
15(16).
PMID: 37630794
Background And Aims: Perioperative treatment is currently the gold standard approach in Europe for locally advanced gastric cancer (GC). Unfortunately, the phenomenon of patients dropping out of treatment has been...
8.
Marisi G, Azzali I, Passardi A, Rebuzzi F, Bartolini G, Urbini M, et al.
Sci Rep
. 2023 Aug;
13(1):12921.
PMID: 37558720
Bevacizumab (Bev) plus chemotherapy is a standard first-line treatment in metastatic colorectal cancer (mCRC), however to date no predictive factors of response have been identified. Results of our previous analysis...
9.
Vannini I, Rossi T, Melloni M, Valgiusti M, Urbini M, Passardi A, et al.
Mol Ther Methods Clin Dev
. 2023 Jun;
29:473-482.
PMID: 37273899
The identification of predictive factors for treatment of pancreatic cancer (PC) is an unmet clinical need. In the present work, we analyzed blood-derived extracellular vesicles (EVs) from patients with advanced...
10.
Reis J, Travado L, Scherrer A, Kosmidis T, Venios S, Laras P, et al.
JMIR Res Protoc
. 2023 Apr;
12:e45475.
PMID: 37083563
Background: According to Europe's Beating Cancer Plan, the number of cancer survivors is growing every year and is now estimated at over 12 million in Europe. A main objective of...